FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O C4	Adam (F	UTICS, INC.	(Middle)		3. t 07/	Issuer Name and Ticker or Trading Symbol C4 Therapeutics, Inc. [CCCC] Date of Earliest Transaction (Month/Day/Year) 07/29/2021							(Che	Relationship of Reporting Person(s) to Issuer eck all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer				vner specify	
(Street) WATER			02472 (Zip)		_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check App Line) X Form filed by One Reporting Person Form filed by More than One Report Person								n					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
			2. Tran: Date (Month		Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3, 4			5. Amou Securitie Benefici Owned F Reporter	es ally Following	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Cod	e v	Amount	(A) (D)	(A) or (D)		Transact	saction(s) r. 3 and 4)			(111511.4)
Common	Common Stock 07/29			9/202	/2021		М		15,00	15,000 A		\$4.98	15	15,000		D			
Common Stock 07/29			9/202)/2021		S ⁽¹⁾		15,00	15,000 D		\$45	0		D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative			3A. Deemed Execution I if any (Month/Day	Date, Transaction Code (Instr					Expirati	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	iy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis		Expiration Date	Title	or Nu of	nount imber ares					
Stock Option (Right to Buy)	\$4.98	07/29/2021			M			15,000	(2)		07/02/2030	Commo Stock		5,000	\$0.00	183,10	8	D	

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
- 2. This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.

Remarks:

/s/ Shoaib Ghias, Attorney-in-

Fact

** Signature of Reporting Person Date

08/02/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.